A Phase I Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 10 Aug 2015 Status changed from suspended to recruiting as per ClinicalTrials.gov record.